Standard

Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery. / Marcucci, Maura; Painter, Thomas W.; Conen, David et al.

In: Trials, Vol. 23, No. 1, 101, 01.2022.

Research output: Contribution to journal › Article › peer-review

Harvard

Marcucci, M, Painter, TW, Conen, D, Leslie, K, Lomivorotov, VV, Sessler, D, Chan, MTV, Borges, FK, Martínez Zapata, MJ, Wang, CY, Xavier, D, Ofori, SN, Landoni, G, Efremov, S, Kleinlugtenbelt, YV, Szczeklik, W, Schmartz, D, Garg, AX, Short, TG, Wittmann, M, Meyhoff, CS, Amir, M, Torres, D, Patel, A, Duceppe, E, Ruetzler, K, Parlow, JL, Tandon, V, Wang, MK, Fleischmann, E, Polanczyk, CA, Jayaram, R, Astrakov, SV, Rao, M, VanHelder, T, Wu, WKK, Cheong, CC, Ayad, S, Abubakirov, M, Kirov, M, Bhatt, K, de Nadal, M, Likhvantsev, V, Iglesisas, PP, Aguado, HJ, McGillion, M, Lamy, A, Whitlock, RP, Roshanov, P, Stillo, D, Copland, I, Vincent, J, Balasubramanian, K, Bangdiwala, SI, Biccard, B, Kurz, A, Srinathan, S, Petit, S, Eikelboom, J, Richards, T, Gross, PL, Alfonsi, P, Guyatt, G, Belley-Cote, E, Spence, J, McIntyre, W, Yusuf, S & Devereaux, PJ 2022, 'Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery', Trials, vol. 23, no. 1, 101. https://doi.org/10.1186/s13063-021-05992-1

APA

Marcucci, M., Painter, T. W., Conen, D., Leslie, K., Lomivorotov, V. V., Sessler, D., Chan, M. T. V., Borges, F. K., Martínez Zapata, M. J., Wang, C. Y., Xavier, D., Ofori, S. N., Landoni, G., Efremov, S., Kleinlugtenbelt, Y. V., Szczeklik, W., Schmartz, D., Garg, A. X., Short, T. G., ... Devereaux, P. J. (2022). Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery. Trials, 23(1), [101]. https://doi.org/10.1186/s13063-021-05992-1

Vancouver

Marcucci M, Painter TW, Conen D, Leslie K, Lomivorotov VV, Sessler D et al. Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery. Trials. 2022 Jan;23(1):101. doi: 10.1186/s13063-021-05992-1

Author

Marcucci, Maura ; Painter, Thomas W. ; Conen, David et al. / Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery. In: Trials. 2022 ; Vol. 23, No. 1.

BibTeX

@article{722b2c69f94d486aa55112b947817bdb,
title = "Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery",
abstract = "Background: For patients undergoing noncardiac surgery, bleeding and hypotension are frequent and associated with increased mortality and cardiovascular complications. Tranexamic acid (TXA) is an antifibrinolytic agent with the potential to reduce surgical bleeding; however, there is uncertainty about its efficacy and safety in noncardiac surgery. Although usual perioperative care is commonly consistent with a hypertension-avoidance strategy (i.e., most patients continue their antihypertensive medications throughout the perioperative period and intraoperative mean arterial pressures of 60 mmHg are commonly accepted), a hypotension-avoidance strategy may improve perioperative outcomes. Methods: The PeriOperative Ischemic Evaluation (POISE)-3 Trial is a large international randomized controlled trial designed to determine if TXA is superior to placebo for the composite outcome of life-threatening, major, and critical organ bleeding, and non-inferior to placebo for the occurrence of major arterial and venous thrombotic events, at 30 days after randomization. Using a partial factorial design, POISE-3 will additionally determine the effect of a hypotension-avoidance strategy versus a hypertension-avoidance strategy on the risk of major cardiovascular events, at 30 days after randomization. The target sample size is 10,000 participants. Patients ≥45 years of age undergoing noncardiac surgery, with or at risk of cardiovascular and bleeding complications, are randomized to receive a TXA 1 g intravenous bolus or matching placebo at the start and at the end of surgery. Patients, health care providers, data collectors, outcome adjudicators, and investigators are blinded to the treatment allocation. Patients on ≥ 1 chronic antihypertensive medication are also randomized to either of the two blood pressure management strategies, which differ in the management of patient antihypertensive medications on the morning of surgery and on the first 2 days after surgery, and in the target mean arterial pressure during surgery. Outcome adjudicators are blinded to the blood pressure treatment allocation. Patients are followed up at 30 days and 1 year after randomization. Discussion: Bleeding and hypotension in noncardiac surgery are common and have a substantial impact on patient prognosis. The POISE-3 trial will evaluate two interventions to determine their impact on bleeding, cardiovascular complications, and mortality. Trial registration: ClinicalTrials.gov NCT03505723. Registered on 23 April 2018.",
keywords = "Cardiovascular complications, Noncardiac surgery, Perioperative bleeding, Perioperative hypotension, Randomized controlled trial, Tranexamic acid, Perioperative Care, Tranexamic Acid/adverse effects, Antifibrinolytic Agents/adverse effects, Humans, Hypotension/chemically induced, Blood Loss, Surgical/prevention & control",
author = "Maura Marcucci and Painter, {Thomas W.} and David Conen and Kate Leslie and Lomivorotov, {Vladimir V.} and Daniel Sessler and Chan, {Matthew T.V.} and Borges, {Flavia K.} and {Mart{\'i}nez Zapata}, {Maria J.} and Wang, {C. Y.} and Denis Xavier and Ofori, {Sandra N.} and Giovanni Landoni and Sergey Efremov and Kleinlugtenbelt, {Ydo V.} and Wojciech Szczeklik and Denis Schmartz and Garg, {Amit X.} and Short, {Timothy G.} and Maria Wittmann and Meyhoff, {Christian S.} and Mohammed Amir and David Torres and Ameen Patel and Emmanuelle Duceppe and Kurtz Ruetzler and Parlow, {Joel L.} and Vikas Tandon and Wang, {Michael K.} and Edith Fleischmann and Polanczyk, {Carisi A.} and Raja Jayaram and Astrakov, {Sergey V.} and Mangala Rao and Tomas VanHelder and Wu, {William K.K.} and Cheong, {Chao Chia} and Sabry Ayad and Marat Abubakirov and Mikhail Kirov and Keyur Bhatt and {de Nadal}, Miriam and Valery Likhvantsev and Iglesisas, {Pilar Paniagua} and Aguado, {Hector J.} and Michael McGillion and Andre Lamy and Whitlock, {Richard P.} and Pavel Roshanov and David Stillo and Ingrid Copland and Jessica Vincent and Kumar Balasubramanian and Bangdiwala, {Shrikant I.} and Bruce Biccard and Andrea Kurz and Sadeesh Srinathan and Shirley Petit and John Eikelboom and Toby Richards and Gross, {Peter L.} and Pascal Alfonsi and Gordon Guyatt and Emily Belley-Cote and Jessica Spence and William McIntyre and Salim Yusuf and Devereaux, {P. J.}",
note = "Funding Information: ED acknowledges Investigator initiated research grants from Roche Diagnostics, Abbott Laboratories and Boehringer Ingelheim; lecture fee and honoraria for participation in advisory board meeting by Roche Diagnostics; support by a Fonds de Recherche en Sante du Quebec salary award. MJM-Z is supported by a Miguel Servet II research contract from the ISCIII (CP1120/00023), Spain. CSM: has co-founded a start-up company, WARD247 ApS, with the aim of pursuing the regulatory and commercial activities of the WARD-project, an Innovation Fund Denmark funded research project on wireless vital signs. CSM also reports direct and indirect research funding to his department from Ferring Pharmaceuticals, Merck, Sharp & Dohme Corp. and Boehringer Ingelheim outside the submitted work as well as lecture fees from Radiometer. DT received speaker honorarium from 3 M and Pfizer. EB-C received grants from Bayer, Roche, and BMS-Pfizer. AP acknowledges to have provided expertise and have been speaker for Laboratory Edwards, 3 M, and MSD laboratories; to have been speaker for Pfizer. AXG is supported by the Dr. Adam Linton Chair in Kidney Health Analytics. PLG has received speaker fees from Bayer, Bristol-Myers-Squibb, Pfizer, Leo Pharma and Valeo. TR reports grants from UK, NIHR HTA; grants from Australian, NHMRC; grants, personal fees and non-financial support from Pharmocosmos; grants, personal fees and non-financial support from Vifor Pharma; grants from UK, NIHR EME; grants from Australian MRFF; grants from Western Australia FHRF; grants and personal fees from Pfizer Australia; personal fees from BioAge Labs, outside the submitted work; and TR is a regular speaker at national and international conferences on anemia, blood transfusion, wound healing and vascular diseases for which he has received expenses for travel, accommodation and sundries. TR has worked with several agencies promoting meetings or healthcare. TR is a director of The Iron Clinic Ltd and director of Veincare London Ltd & Veincare WA also TR is the Vascular lead for 18-week wait Ltd. All the other co-authors report no conflict of interest. Funding Information: The study is supported by the following grants: Canadian Institutes of Health Research (CIHR) Foundation Grant awarded to PJD (FDN-143302), Canada; General Research Fund 14104419, Research Grant Council, Hong Kong SAR, China; and National Health and Medical Research Council, Funding Schemes, NHMRC Project Grant 1162362, Australia. MM holds a McMaster University Department of Medicine Career Research Award and a Physicians' Services Incorporated (PSI) Foundation Mid-Career Clinical Research Award to support her research work in perioperative medicine. FKB holds a McMaster University Department of Medicine Career Research Award to support her research work in perioperative medicine. Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
month = jan,
doi = "10.1186/s13063-021-05992-1",
language = "English",
volume = "23",
journal = "Trials",
issn = "1468-6708",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery

AU - Marcucci, Maura

AU - Painter, Thomas W.

AU - Conen, David

AU - Leslie, Kate

AU - Lomivorotov, Vladimir V.

AU - Sessler, Daniel

AU - Chan, Matthew T.V.

AU - Borges, Flavia K.

AU - Martínez Zapata, Maria J.

AU - Wang, C. Y.

AU - Xavier, Denis

AU - Ofori, Sandra N.

AU - Landoni, Giovanni

AU - Efremov, Sergey

AU - Kleinlugtenbelt, Ydo V.

AU - Szczeklik, Wojciech

AU - Schmartz, Denis

AU - Garg, Amit X.

AU - Short, Timothy G.

AU - Wittmann, Maria

AU - Meyhoff, Christian S.

AU - Amir, Mohammed

AU - Torres, David

AU - Patel, Ameen

AU - Duceppe, Emmanuelle

AU - Ruetzler, Kurtz

AU - Parlow, Joel L.

AU - Tandon, Vikas

AU - Wang, Michael K.

AU - Fleischmann, Edith

AU - Polanczyk, Carisi A.

AU - Jayaram, Raja

AU - Astrakov, Sergey V.

AU - Rao, Mangala

AU - VanHelder, Tomas

AU - Wu, William K.K.

AU - Cheong, Chao Chia

AU - Ayad, Sabry

AU - Abubakirov, Marat

AU - Kirov, Mikhail

AU - Bhatt, Keyur

AU - de Nadal, Miriam

AU - Likhvantsev, Valery

AU - Iglesisas, Pilar Paniagua

AU - Aguado, Hector J.

AU - McGillion, Michael

AU - Lamy, Andre

AU - Whitlock, Richard P.

AU - Roshanov, Pavel

AU - Stillo, David

AU - Copland, Ingrid

AU - Vincent, Jessica

AU - Balasubramanian, Kumar

AU - Bangdiwala, Shrikant I.

AU - Biccard, Bruce

AU - Kurz, Andrea

AU - Srinathan, Sadeesh

AU - Petit, Shirley

AU - Eikelboom, John

AU - Richards, Toby

AU - Gross, Peter L.

AU - Alfonsi, Pascal

AU - Guyatt, Gordon

AU - Belley-Cote, Emily

AU - Spence, Jessica

AU - McIntyre, William

AU - Yusuf, Salim

AU - Devereaux, P. J.

N1 - Funding Information: ED acknowledges Investigator initiated research grants from Roche Diagnostics, Abbott Laboratories and Boehringer Ingelheim; lecture fee and honoraria for participation in advisory board meeting by Roche Diagnostics; support by a Fonds de Recherche en Sante du Quebec salary award. MJM-Z is supported by a Miguel Servet II research contract from the ISCIII (CP1120/00023), Spain. CSM: has co-founded a start-up company, WARD247 ApS, with the aim of pursuing the regulatory and commercial activities of the WARD-project, an Innovation Fund Denmark funded research project on wireless vital signs. CSM also reports direct and indirect research funding to his department from Ferring Pharmaceuticals, Merck, Sharp & Dohme Corp. and Boehringer Ingelheim outside the submitted work as well as lecture fees from Radiometer. DT received speaker honorarium from 3 M and Pfizer. EB-C received grants from Bayer, Roche, and BMS-Pfizer. AP acknowledges to have provided expertise and have been speaker for Laboratory Edwards, 3 M, and MSD laboratories; to have been speaker for Pfizer. AXG is supported by the Dr. Adam Linton Chair in Kidney Health Analytics. PLG has received speaker fees from Bayer, Bristol-Myers-Squibb, Pfizer, Leo Pharma and Valeo. TR reports grants from UK, NIHR HTA; grants from Australian, NHMRC; grants, personal fees and non-financial support from Pharmocosmos; grants, personal fees and non-financial support from Vifor Pharma; grants from UK, NIHR EME; grants from Australian MRFF; grants from Western Australia FHRF; grants and personal fees from Pfizer Australia; personal fees from BioAge Labs, outside the submitted work; and TR is a regular speaker at national and international conferences on anemia, blood transfusion, wound healing and vascular diseases for which he has received expenses for travel, accommodation and sundries. TR has worked with several agencies promoting meetings or healthcare. TR is a director of The Iron Clinic Ltd and director of Veincare London Ltd & Veincare WA also TR is the Vascular lead for 18-week wait Ltd. All the other co-authors report no conflict of interest. Funding Information: The study is supported by the following grants: Canadian Institutes of Health Research (CIHR) Foundation Grant awarded to PJD (FDN-143302), Canada; General Research Fund 14104419, Research Grant Council, Hong Kong SAR, China; and National Health and Medical Research Council, Funding Schemes, NHMRC Project Grant 1162362, Australia. MM holds a McMaster University Department of Medicine Career Research Award and a Physicians' Services Incorporated (PSI) Foundation Mid-Career Clinical Research Award to support her research work in perioperative medicine. FKB holds a McMaster University Department of Medicine Career Research Award to support her research work in perioperative medicine. Publisher Copyright: © 2022, The Author(s).

PY - 2022/1

Y1 - 2022/1

N2 - Background: For patients undergoing noncardiac surgery, bleeding and hypotension are frequent and associated with increased mortality and cardiovascular complications. Tranexamic acid (TXA) is an antifibrinolytic agent with the potential to reduce surgical bleeding; however, there is uncertainty about its efficacy and safety in noncardiac surgery. Although usual perioperative care is commonly consistent with a hypertension-avoidance strategy (i.e., most patients continue their antihypertensive medications throughout the perioperative period and intraoperative mean arterial pressures of 60 mmHg are commonly accepted), a hypotension-avoidance strategy may improve perioperative outcomes. Methods: The PeriOperative Ischemic Evaluation (POISE)-3 Trial is a large international randomized controlled trial designed to determine if TXA is superior to placebo for the composite outcome of life-threatening, major, and critical organ bleeding, and non-inferior to placebo for the occurrence of major arterial and venous thrombotic events, at 30 days after randomization. Using a partial factorial design, POISE-3 will additionally determine the effect of a hypotension-avoidance strategy versus a hypertension-avoidance strategy on the risk of major cardiovascular events, at 30 days after randomization. The target sample size is 10,000 participants. Patients ≥45 years of age undergoing noncardiac surgery, with or at risk of cardiovascular and bleeding complications, are randomized to receive a TXA 1 g intravenous bolus or matching placebo at the start and at the end of surgery. Patients, health care providers, data collectors, outcome adjudicators, and investigators are blinded to the treatment allocation. Patients on ≥ 1 chronic antihypertensive medication are also randomized to either of the two blood pressure management strategies, which differ in the management of patient antihypertensive medications on the morning of surgery and on the first 2 days after surgery, and in the target mean arterial pressure during surgery. Outcome adjudicators are blinded to the blood pressure treatment allocation. Patients are followed up at 30 days and 1 year after randomization. Discussion: Bleeding and hypotension in noncardiac surgery are common and have a substantial impact on patient prognosis. The POISE-3 trial will evaluate two interventions to determine their impact on bleeding, cardiovascular complications, and mortality. Trial registration: ClinicalTrials.gov NCT03505723. Registered on 23 April 2018.

AB - Background: For patients undergoing noncardiac surgery, bleeding and hypotension are frequent and associated with increased mortality and cardiovascular complications. Tranexamic acid (TXA) is an antifibrinolytic agent with the potential to reduce surgical bleeding; however, there is uncertainty about its efficacy and safety in noncardiac surgery. Although usual perioperative care is commonly consistent with a hypertension-avoidance strategy (i.e., most patients continue their antihypertensive medications throughout the perioperative period and intraoperative mean arterial pressures of 60 mmHg are commonly accepted), a hypotension-avoidance strategy may improve perioperative outcomes. Methods: The PeriOperative Ischemic Evaluation (POISE)-3 Trial is a large international randomized controlled trial designed to determine if TXA is superior to placebo for the composite outcome of life-threatening, major, and critical organ bleeding, and non-inferior to placebo for the occurrence of major arterial and venous thrombotic events, at 30 days after randomization. Using a partial factorial design, POISE-3 will additionally determine the effect of a hypotension-avoidance strategy versus a hypertension-avoidance strategy on the risk of major cardiovascular events, at 30 days after randomization. The target sample size is 10,000 participants. Patients ≥45 years of age undergoing noncardiac surgery, with or at risk of cardiovascular and bleeding complications, are randomized to receive a TXA 1 g intravenous bolus or matching placebo at the start and at the end of surgery. Patients, health care providers, data collectors, outcome adjudicators, and investigators are blinded to the treatment allocation. Patients on ≥ 1 chronic antihypertensive medication are also randomized to either of the two blood pressure management strategies, which differ in the management of patient antihypertensive medications on the morning of surgery and on the first 2 days after surgery, and in the target mean arterial pressure during surgery. Outcome adjudicators are blinded to the blood pressure treatment allocation. Patients are followed up at 30 days and 1 year after randomization. Discussion: Bleeding and hypotension in noncardiac surgery are common and have a substantial impact on patient prognosis. The POISE-3 trial will evaluate two interventions to determine their impact on bleeding, cardiovascular complications, and mortality. Trial registration: ClinicalTrials.gov NCT03505723. Registered on 23 April 2018.

KW - Cardiovascular complications

KW - Noncardiac surgery

KW - Perioperative bleeding

KW - Perioperative hypotension

KW - Randomized controlled trial

KW - Tranexamic acid

KW - Perioperative Care

KW - Tranexamic Acid/adverse effects

KW - Antifibrinolytic Agents/adverse effects

KW - Humans

KW - Hypotension/chemically induced

KW - Blood Loss, Surgical/prevention & control

UR - http://www.scopus.com/inward/record.url?scp=85123974840&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/e37eac88-62db-3789-b795-d702f97651ca/

U2 - 10.1186/s13063-021-05992-1

DO - 10.1186/s13063-021-05992-1

M3 - Article

C2 - 35101083

AN - SCOPUS:85123974840

VL - 23

JO - Trials

JF - Trials

SN - 1468-6708

IS - 1

M1 - 101

ER -

ID: 35429261